bioAffinity Technologies (NASDAQ:BIAF) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of bioAffinity Technologies (NASDAQ:BIAF) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings downgraded bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

bioAffinity Technologies Price Performance

bioAffinity Technologies stock opened at $1.88 on Friday. The company has a current ratio of 1.36, a quick ratio of 2.58 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $8.52 million, a PE ratio of -0.16 and a beta of -1.19. bioAffinity Technologies has a 12 month low of $0.69 and a 12 month high of $15.00. The stock has a 50-day moving average price of $2.71 and a two-hundred day moving average price of $1.87.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Friday, May 8th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($2.40) by $1.59. The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $1.48 million. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.

Institutional Investors Weigh In On bioAffinity Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the stock. J. Safra Sarasin Holding AG acquired a new stake in shares of bioAffinity Technologies in the first quarter valued at about $164,000. Geode Capital Management LLC acquired a new stake in shares of bioAffinity Technologies in the fourth quarter valued at about $36,000. Scientech Research LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter valued at about $49,000. Finally, Sabby Management LLC acquired a new stake in shares of bioAffinity Technologies in the third quarter valued at about $719,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.